Overview: Inhibin A Pregnancy TestIntroduction: The Inhibin A Pregnancy Test measures inhibin A to assess pregnancy complications, causing miscarriage risk. Following 2023 ACOG guidelines, it uses immunoassay for high specificity, supporting pregnancy screening. This test is critical for guiding diagnosis, management, and improving outcomes in endocrinology for pregnant patients with suspected complications, such as preeclampsia or fetal abnormalities.
Other Names: Inhibin A Preg Assay, Pregnancy Complication Test.
FDA Status: Laboratory-developed test (LDT), meeting endocrinology standards for diagnostic accuracy.
Historical Milestone: Inhibin A testing for pregnancy began in the 1990s with prenatal screening research. Immunoassay-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures inhibin A to assess pregnancy complications, guides management, and evaluates miscarriage risk.
Test Parameters: 1. Inhibin A (Pregnancy)
Pretest Condition: Fasting 10-12 hours required. Collect serum or plasma. Report history of pregnancy complications, miscarriage, or fetal abnormalities.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document pregnancy history, miscarriage, preeclampsia, or fetal abnormalities. Include current medications, especially prenatal supplements.
Consent: Written consent required, detailing the tests purpose, pregnancy complication implications, and risks of blood collection.
Procedural Considerations: Uses immunoassay to measure inhibin A in serum or plasma. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for prenatal screening.
Factors Affecting Result Accuracy: Hemolysis, lipemia, or improper sample storage can affect results. Non-fasting samples may reduce accuracy.
Clinical Significance: Elevated inhibin A suggests pregnancy complications (e.g., preeclampsia, Down syndrome), guiding monitoring or intervention. Normal levels may require further prenatal testing.
Specialist Consultation: Consult an obstetrician or maternal-fetal medicine specialist for result interpretation and management.
Additional Supporting Tests: AFP, hCG, or ultrasound to assess pregnancy complications.
Test Limitations: Not specific to one complication; clinical correlation is needed. Other conditions may elevate inhibin A.
References: ACOG Prenatal Screening Guidelines, 2023; American Journal of Obstetrics and Gynecology, Wald NJ, 2022.
